Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
- 1 October 2011
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 164 (4), 1079-1106
- https://doi.org/10.1111/j.1476-5381.2011.01302.x
Abstract
Experimental autoimmune encephalomyelitis (EAE) is the most commonly used experimental model for the human inflammatory demyelinating disease, multiple sclerosis (MS). EAE is a complex condition in which the interaction between a variety of immunopathological and neuropathological mechanisms leads to an approximation of the key pathological features of MS: inflammation, demyelination, axonal loss and gliosis. The counter-regulatory mechanisms of resolution of inflammation and remyelination also occur in EAE, which, therefore can also serve as a model for these processes. Moreover, EAE is often used as a model of cell-mediated organ-specific autoimmune conditions in general. EAE has a complex neuropharmacology, and many of the drugs that are in current or imminent use in MS have been developed, tested or validated on the basis of EAE studies. There is great heterogeneity in the susceptibility to the induction, the method of induction and the response to various immunological or neuropharmacological interventions, many of which are reviewed here. This makes EAE a very versatile system to use in translational neuro-and immunopharmacology, but the model needs to be tailored to the scientific question being asked. While creating difficulties and underscoring the inherent weaknesses of this model of MS in straightforward translation from EAE to the human disease, this variability also creates an opportunity to explore multiple facets of the immune and neural mechanisms of immune-mediated neuroinflammation and demyelination as well as intrinsic protective mechanisms. This allows the eventual development and preclinical testing of a wide range of potential therapeutic interventions.Keywords
This publication has 295 references indexed in Scilit:
- Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccinesVaccine, 2011
- Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral SclerosisArchives of Neurology, 2010
- Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical StudiesTransplantation and Cellular Therapy, 2010
- Modulation of Cannabinoid Receptor Activation as a Neuroprotective Strategy for EAE and StrokeJournal of Neuroimmune Pharmacology, 2009
- Loss of Na+ channel β2 subunits is neuroprotective in a mouse model of multiple sclerosisMolecular and Cellular Neuroscience, 2009
- Human bone marrow‐derived mesenchymal stem cells induce Th2‐polarized immune response and promote endogenous repair in animal models of multiple sclerosisGlia, 2009
- Bladder dysfunction in mice with experimental autoimmune encephalomyelitisJournal of Neuroimmunology, 2008
- Refining genetic associations in multiple sclerosisThe Lancet Neurology, 2008
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983